Last $16.89 USD
Change Today +0.095 / 0.57%
Volume 5.6M
BSX On Other Exchanges
Symbol
Exchange
New York
As of 2:06 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
$16.82
Previous Close
$16.79
Day High
$17.07
Day Low
$16.80
52 Week High
03/2/15 - $17.26
52 Week Low
10/16/14 - $11.10
Market Cap
22.4B
Average Volume 10 Days
14.7M
EPS TTM
$0.45
Shares Outstanding
1.3B
EX-Date
--
P/E TM
37.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to diagnose and treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides products to treat diseases of the digestive and pulmonary systems; stone management products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices to treat urological and gynecological disorders; spinal cord stimulator systems; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

24,000 Employees
Last Reported Date: 02/25/15
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation Announces Board Changes

Boston Scientific Corporation announced the election of Charles J. Dockendorff and Stephen P. MacMillan to its board of directors, effective April 1, 2015. Two current members of the board, Uwe E. Reinhardt and Bruce L. Byrnes, will not stand for re-election at the company's annual meeting of stockholders in May 2015. Charles J. Dockendorff was formerly the executive vice president and chief financial officer of Covidien plc. Mr. Dockendorff currently serves on the board of directors of Haemonetics Corporation and Keysight Technologies. Stephen P. MacMillan is currently the president and chief executive officer of Hologic. Previously, Mr. MacMillan served as president and chief executive officer of Stryker Corporation. He currently serves on the board of directors of Alere Inc.

Boston Scientific Corporation, American Medical Systems - M&A Call

To discuss definitive agreement between Boston Scientific Corporation and Endo International plc to acquire the American Medical Systems urology portfolio

Boston Scientific Corporation Eyes Acquisitions

FD (Fair Disclosure) Wire March 2, 2015 Monday Boston Scientific Corp Announces Definitive Agreement To Acquire American Medical Systems' Urology Portfolio For Up To $1.65 Billion Corporate Call - Final LENGTH:Â 4999 words Corporate Participants * Susan Lisa Boston Scientific Corporation - IR * Mike Mahoney Boston Scientific Corporation - President & CEO * Dan Brennan Boston Scientific Corporation - EVP & CFO * Karen Prange Boston Scientific Corporation - SVP and Pres, Urology & Women's Health Conference Call Participants * David Lewis Morgan Stanley - Analyst * Mike Weinstein JPMorgan - Analyst * Bob Hopkins BofA Merrill Lynch - Analyst * Bruce Nudell Credit Suisse - Analyst * Larry Biegelsen Wells Fargo Securities - Analyst * Brooks West Piper Jaffray & Co. - Analyst * David Roman Goldman Sachs - Analyst * Matt Taylor Barclays Capital - Analyst * Kristen Stewart Deutsche Bank - Analyst Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific investor update call. (Operator Instructions) As a reminder, this conference is being recorded. I will now turn the conference over to our host, Susan Lisa. Please go ahead. SUSAN LISA, IR, BOSTON SCIENTIFIC CORPORATION: Thank you, Karen. Good morning, everyone, and thanks for joining us on short notice. With me on today's call are Mike Mahoney, President and Chief Executive Officer; Dan Brennan, Executive Vice President and Chief Financial Officer; and Karen Prange, Senior Vice President and President, Urology and Women's Health. We issued a press release earlier this morning announcing that we have entered into a definitive agreement with Endo Health Solutions to acquire the AMS urology portfolio, which includes the men's health and prostate health businesses, for up to $1.6 billion in upfront cash and a potential additional $50 million milestone based on 2016 sales. We have posted a copy of that release, reconciliations of the non-GAAP measures used in today's call, and additional financial and operational highlights under the Investor Relations section of our website under the heading financial information, quarterly results, and non-GAAP reconciliations. The duration of this morning's call will be approximately 30 minutes. Mike and Dan will give brief summary remarks and will host a Q&A session, during which Mike and Dan will be joined by Karen. Before we begin I would like to remind everyone that this call contains forward-looking statements within the meaning of federal securities laws which may be identified by words like anticipate, expect, believe, estimate, and other similar words. They include, among other things, statement about the proposed acquisition including the closing and integration of the acquisition; expected accretion and dilution; expected synergies, growth, and market share; cost savings and growth opportunities; our cash flow and expected use; our financial performance including sales, margins, earnings, and other full-year 2015 guidance as well as our tax rates and other expenses. Actual results may differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include those described in the Risk Factors section of our most recent 10-K and subsequent 10-Qs and 8-Ks to be filed with the SEC. These statements speak only as of today's date and we disclaim any intention or obligation to update them. At this point, I will turn over to Mike for his comments. Mike? MIKE MAHONEY, PRESIDENT & CEO, BOSTON SCIENTIFIC CORPORATION: Thank you, Susie. Good morning. Thanks to all of you for joining the phone on such short notice. I will give brief remarks on the strategic rationale for the transaction and the market opportunity. Dan will then give the financial highlights and then we will leave about 15 minutes for your questions. We will plan on ending the call by 9 AM this morning. We have consistently stated that our preferred M&A targets are those with a strong strategic fit and compelling financials. More specifically, we are pursuing transactions that strategically help us to forge category leadership that are in attractive global markets and that deliver meaningful innovation. Financially, our M&A strategy seeks to generate strong risk-adjusted returns on invested capital, while enabling near-term revenue and cost synergies as well as strong EPS accretion. The acquisition of AMS Men's Health and Prostate Health business checks all the boxes that we look for in a transaction. Number one, men's health is an attractive global market. The urology device market is a multibillion-dollar global market, growing low to mid single digits. In fact, in 2014 the Boston Scientific Urology and Women's Health business delivered strong results, growing operational revenue 7%, while expanding our business internationally. In the urology market there a large unmet patient needs and solid demographic factors that drive the underlying global growth rate. These factors include an aging population with the desire to maintain a high quality of life; expanded access, particularly internationally; more minimally invasive solutions; and increased patient and physician awareness of these treatments. As usual, our goal is to grow revenue in these segments faster than the market growth rate. Number two, this deal establishes a clear leadership position for BSC. By combining the BSC Urology and Women's Health portfolio with the AMS Men's Health and Prostate Health business, we are creating a nearly $1 billion global market leader. The combined business will offer a comprehensive portfolio with market-leading positions across the five major segments including stone management, erectile restoration, BPH treatment, male urinary incontinence, and pelvic floor repair. This broad portfolio, combined with the largest global footprint, provides unique opportunities for BSC to partner with urologists and hospital customers while driving meaningful innovation for patients. Number three, this transaction offers strong financial returns with an ROIC that is expected to exceed our cost of capital by 2017, with positive accretion to adjusted earnings in 2016 and increasingly accretive thereafter. The adjusted operating margin profile of the AMS Men's Health and Prostate Health business is attractive, in the low 30% range, and projected to be immediately accretive to BSC corporate operating margins. We also expect to achieve in excess of $15 million in deal-related synergies by the end of 2018. Since 2011, the AMS Men's Health and Prostate Health business has grown operational revenue 2% to 3% annually. We believe that BSC will improve that historical growth profile to align with our overall BSC revenue guidance at 3% to 6% operational growth. We project improved growth rate due to the power of the combined urology portfolio, international expansion opportunities, our combined commercial footprint, and the focus of a leading medical device company. Fourth, this transaction is strategically compelling for BSE overall as it further strengthens our portfolio diversification into attractive global markets. In addition, it furthers our goal of category leadership in each of our businesses. Rather than breadth, our strategy is depth, depth within specific service lines of the hospital, providing a comprehensive portfolio of solutions to our hospital and physician customers. Finally, we look forward to welcoming the AMS Urology team to Boston Scientific. Boston Scientific's culture, our values, and the winning spirit of our employees continues to be a key factor in

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $16.89 USD +0.095

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥2,000 JPY +20.00
Coloplast A/S kr526.50 DKK +8.00
Olympus Corp ¥4,175 JPY -125.00
St Jude Medical Inc $67.50 USD +0.36
Terumo Corp ¥3,245 JPY +20.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 3.4x
Price/Cash Flow 69.9x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.